title: [Combined therapy with chenodeoxycholic acid and ursodeoxycholic acid of radiolucent biliary lithiasis].
abstract: 27 patients with radiolucent biliary stones in normofunctioning gall bladder were treated with a combination of CDCA and UDCA (CDCA doses = 7.7 mg/kg/day; UDCA--6.5 mg/kg/day); only 23 continued in the study for at least one year. The reasons for leaving were in one case the necessity of a cholecystectomy and treatment interruption in 3 cases. The rate of complete dissolution was of 39%, being of 17% the partial dissolution rate. The only biochemical alteration was the increase of HDL cholesterol at 9 and 12 months of treatment (p less than 0.05 and p less than 0.01 respectively). Transient diarrhea was seen in 17% of the patients and it did not require treatment. The incidence of liver colic during the year before treatment was 26% and it decreased during the 1st year of treatment to 4%. The non-specific dyspepsia observed during the year before treatment was of 48%, and decreased to 17% during the first year of treatment. Only one patient developed calcification of the gallstone, 12 months after treatment.
authors.forename: F
authors.initials: F
authors.lastname: Pérez Aguilar
authors.forename: M
authors.initials: M
authors.lastname: Breto
authors.forename: A
authors.initials: A
authors.lastname: del Val
authors.forename: J
authors.initials: J
authors.lastname: Berenguer
mesh_terms: D000368:Aged; D002635:Chenodeoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D002769:Cholelithiasis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography; D014580:Ursodeoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002635:Chenodeoxycholic Acid; D014580:Ursodeoxycholic Acid
vernacular_title: Tratamiento combinado con los ácidos quenodesoxicólico (AQDC) y ursodesoxicólico (AUDC) en la litiasis biliar radiotransparente.